2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 375

Evaluation of RAPID3 with Minimal Joint Count and ACR/EULAR Provisional Remission Definitions As Predictors of Future Good Radiographic + Functional Outcome in a Double-Blind, Phase 3, Randomized Controlled Trial of Tocilizumab
Abstract Number: 100

Evaluation of Real World Experience with Non-Biologic DMARD in the Treatment of RA: Data from an Electronic Health Record Database
Abstract Number: 2937

Evaluation of Referral Models for Axial Spondyloarthritis in Primary Care in the Spondyloarthritis Caught Early Cohort
Abstract Number: 1165

Evaluation of Symptom Control Among Treated Gout Patients in the United States, United Kingdom, and Germany
Abstract Number: 459

Evaluation of the Effect of Tofacitinib on Measured Glomerular Filtration Rate in Patients with Active Rheumatoid Arthritis
Abstract Number: 3015

Evaluation of the effuc Educational Needs Assessment Tool (ENAT) Focused Patient Education on Health Outcomes in Patients with Rheumatolid Arthritis – a Randomised Controlled Trial
Abstract Number: 581

Evaluation of the Nonsteroidal Anti-Inflammatory Drug-Sparing Effect of Etanercept in Axial Spondyloarthritis: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Abstract Number: 1584

Evaluation of the Patient Acceptable Symptom State in Patients with Psoriatic Arthritis
Abstract Number: 1529

Evaluation of the Pharmacokinetics and Safety of the Interactions Between the Anti-Interleukin-6 Monoclonal Antibody Sirukumab and Cytochrome P450 Activities in Patients with Rheumatoid Arthritis
Abstract Number: 467

Evaluation of the Rabbit Risk Score for Serious Infections in a UK Anti-TNF Treatment Cohort
Abstract Number: 2083

Evaporative Dry-Eye Disease and Aqueous Deficient Dry-Eye Disease Associated with Fibromyalgia
Abstract Number: 1841

Eventual Joint Failure and Surgery Rates in Rheumatoid Arthritis Remain High in Patients with Moderate Disease Activity in the First 5 Years of Disease
Abstract Number: 2282

Evidence Based Recommendatinos for Diagnosis and Management of Mevalonate Kinase Deficiency (MKD)
Abstract Number: 2279

Evidence Based Recommendations for Diagnosis and Management of Tumor Necrosis Factor Receptor-1 Associated Periodic Syndrome (TRAPS)
Abstract Number: 1231

Evidence Based Recommendations for Genetic Diagnosis of Familial Mediterranean Fever

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].